Journal article

Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours

Suzanne George, Jayesh Desai, J Paul Eder, Judith Manola, Dauid P Ryan, Leonard J Appleman, George D Demetri

EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2006

Abstract

The aim of this study was to determine the safety and maximum-tolerated doses of imatinib combined with cytotoxic chemotherapy (either gemcitabine or doxorubicin). Patients with advanced solid tumours were enrolled separately in two different combinations of imatinib with chemotherapy (imatinib + gemcitabine or imatinib + doxorubicin). A standard modified Fibonacci inter-cohort dose escalation was planned for each combination. Sixteen patients were accrued. Seven patients received gemcitabine and imatinib. A separate cohort of nine patients received imatinib and doxorubicin. In both groups, dose-limiting toxicity (DLT) was observed at the initial dose level requiring dose reductions for subs..

View full abstract